LifeMD, Inc.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of those who acquired LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ:LFMD) securities during the period of May 7, 2025 through August 5, 2025, inclusive (“the Class Period”). Investors have until October 27, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
 

According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants materially overstated LifeMDs competitive position; (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.